103 products were found matching your search for Leukemia in 2 shops:

Gently used. May include previous owner's signature or bookplate on the front endpaper, sticker on back and/or remainder mark on text block.

Adult Leukemia summarizes advances in leukemia biology and treatment. It discusses the most successful treatments currently available and examines the remaining obstacles to a cure. Dr. Wiernik's team at New York Medical College has done seminal work in clinical investigation as well as patient management in the leukemias. The subject lends itself particularly well to color illustrations, a key feature of the American Cancer Society Atlas of Clinical Oncology series. This book is an essential reference tool for medical and radiation oncologists and for hematologists.

New insights into the molecular biology of childhood leukemias have stimulated numerous advances in diagnostic methods, strategies for risk assessment and the development of novel therapy for genetic subtypes of the diseases. Fully revised and updated, this new edition of Childhood Leukemias provides the most comprehensive, clinically-oriented and authoritative reference dedicated to these diseases. Beginning with an overview of history, cell biology, and pathology, subsequent chapters review approaches in the evaluation and management of specific leukemias, new therapeutic development and the unique pharmacodynamics and pharmacogenetics of individual patients. New chapters include epigenetics of leukemias, leukemias in patients with Down syndrome and leukemia in adolescents and young adults. The final section covers the complications associated with the disease or its treatment and supportive care during and after treatment. Authored by leading experts, this is a 'must-have' for any physician or investigator who deals with leukemias in childhood.

Supplements included Ship within 24hrs. Satisfaction 100% guaranteed. APO/FPO addresses supported

Adult Leukemia summarizes advances in leukemia biology and treatment. It discusses the most successful treatments currently available and examines the remaining obstacles to a cure. Dr. Wiernik's team at New York Medical College has done seminal work in clinical investigation as well as patient management in the leukemias. The subject lends itself particularly well to color illustrations, a key feature of the American Cancer Society Atlas of Clinical Oncology series. This book is an essential reference tool for medical and radiation oncologists and for hematologists.

Approximately 4,500 children and teens are diagnosed with leukemia in the United States and Canada each year. The illness and its treatment can have a devastating effect on family, friends, classmates, and the larger community. This newly updated edition of Childhood Leukemia contains the information and support parents need during this difficult time, including:New treatments such as immunotherapy, tailoring drugs dosages to children's genetic profiles, and ways to deal with side effects.Advice on how to cope with procedures, hospitalization, school, family, and financial issues.Tips for forming a partnership with the medical team.Poignant and practical stories from family members.Updated resources for medical information, emotional support, and financial assistance.Parents who read this book will find understandable medical information and emotional support.

Approximately 4,500 children and teens are diagnosed with leukemia in the United States and Canada each year. The illness and its treatment can have a devastating effect on family, friends, classmates, and the larger community. This newly updated edition of Childhood Leukemia contains the information and support parents need during this difficult time, including:New treatments such as immunotherapy, tailoring drugs dosages to children's genetic profiles, and ways to deal with side effects.Advice on how to cope with procedures, hospitalization, school, family, and financial issues.Tips for forming a partnership with the medical team.Poignant and practical stories from family members.Updated resources for medical information, emotional support, and financial assistance.Parents who read this book will find understandable medical information and emotional support.

Used book that is in excellent condition. May show signs of wear or have minor defects.

This book provides a comprehensive overview on the clinical issues and biology of acute promyelocytic leukemia (APL) and on the molecular mechanisms of targeted therapy with ATRA and ATO. The text covers major topics such as the pathophysiology of APL coagulopathy, biologic and clinical differences between children and adults with APL, and the role of minimal residual disease monitoring. Additionally, the book summarizes historical, current, and future treatment strategies in both adults and children, while highlighting the most recent therapeutic recommendations for relapsed disease and the evolving indications for autologous and allogeneic stem cell transplant. This volume also features chapters focusing on secondary APL and therapy, late effects, rare presentations such as APL in the elderly and during pregnancy, and rare APL variants that may represent therapeutic challenges.Written by top experts in the field, Acute Promyelocytic Leukemia: A Clinical Guide is a valuable resource for clinicians and researchers who treat and investigate this disease in children and adults.

This item is printed on demand - it takes 3-4 days longer - Neuware -Chronic lymphocytic leukemia is the most common leukemia affecting mainly elderly individuals and follows an extremely variable course, with survival ranging from months to decades. Several characteristics of CLL facilitate basic and translational research including the high population prevalence, the easily obtainable malignant cells through venous phlebotomy, the asymptomatic phase in most patients that allows for longitudinal evaluation, and the relatively long disease-specific survival. Consensus guidelines for treatment of patients with CLL have been proposed by the ESMO Clinical Practice Guidelines, and recently recommended that the current use of prognostic tools for patients with newly diagnosed CLL should include staging (Rai or Binet), lymphocyte doubling time (LDT), Beta-2 microglobulin (beta2M), CD38 and ZAP-70 markers, CLL-relevant fluorescence in situ hybridization (FISH) panel, and, if available, IgVH gene mutation status. 72 pp. Englisch

This book provides an overview of the key developments in both acute lymphocytic leukemia and acute myeloid leukemia with a comprehensive guide to the epidemiology, pathogenesis, etiology, clinical manifestations, classification, diagnosis, and staging as well as the most recent developments in the therapeutic landscape for acute leukemia. The Handbook of Acute Leukemia offers readers a key resource into the future outlook for patients with leukemia and is edited and authored by internationally renowned experts in the field. Leukemia is cancer of the white blood cells and acute leukemia means the condition progresses rapidly and aggressively, requiring immediate treatment. Acute leukemia is classified according to the type of white blood cells that are affected: either lymphocytes and myeloid cells.

This book provides an overview of the key developments in both acute lymphocytic leukemia and acute myeloid leukemia with a comprehensive guide to the epidemiology, pathogenesis, etiology, clinical manifestations, classification, diagnosis, and staging as well as the most recent developments in the therapeutic landscape for acute leukemia. The Handbook of Acute Leukemia offers readers a key resource into the future outlook for patients with leukemia and is edited and authored by internationally renowned experts in the field. Leukemia is cancer of the white blood cells and acute leukemia means the condition progresses rapidly and aggressively, requiring immediate treatment. Acute leukemia is classified according to the type of white blood cells that are affected: either lymphocytes and myeloid cells.

Book is in NEW condition. 1.27

Chronic Lymphocytic Leukemia (CLL) is a disease which has a variable course, and survival rates range from months to decades. It is evident that clinical heterogeneity represents biologic variety with two main subtypes in terms of cellular multiplication,

Chronic Lymphocytic Leukemia (CLL) is a disease which has a variable course, and survival rates range from months to decades. It is evident that clinical heterogeneity represents biologic variety with two main subtypes in terms of cellular multiplication,

This is the story of Tom Robbins - father, husband, pastor, cancer survivor. With surprising honesty, Tom shares his experience with acute myeloid leukemia and the lessons God taught him through that experience.

Toxic waste, contaminated water, cancer clusters―these phrases suggest deception and irresponsibility. But more significantly, they are watchwords for a growing struggle between communities, corporations, and government. In No Safe Place, sociologists, public policy professionals, and activists will learn how residents of Woburn, Massachusetts discovered a childhood leukemia cluster and eventually sued two corporate giants. Their story gives rise to questions important to any concerned citizen: What kind of government regulatory action can control pollution? Just how effective can the recent upsurge of popular participation in science and technology be? Phil Brown, a medical sociologist, and Edwin Mikkelsen, psychiatric consultant to the plaintiffs, look at the Woburn experience in light of similar cases, such as Love Canal, in order to show that toxic waste contamination reveals fundamental flaws in the corporate, governmental, and scientific spheres.The authors strike a humane, constructive note amidst chilling odds, advocating extensive lay involvement based on the Woburn model of civic action. Finally, they propose a safe policy for toxic wastes and governmental/corporate responsibility. Woburn, the authors predict, will become a code word for environmental struggles.

Unread book in perfect condition.

Book is in NEW condition. 0.42

This book provides an unprecedented overview of "Targeted Therapies" for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make "leukemia history" in the near future.